Cargando…
Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
BACKGROUND: There is no established treatment after failure of proven therapies for patients with metastatic renal cell carcinoma. CASE PRESENTATION: A 66-year-old Japanese man with metastatic renal cell carcinoma became refractory to interferon α and sunitinib therapies. He started treatment with a...
Autores principales: | Murata, Masaki, Ikeda, Yohei, Hasegawa, Go, Nakagawa, Yuki, Nishiyama, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475964/ https://www.ncbi.nlm.nih.gov/pubmed/31006385 http://dx.doi.org/10.1186/s13256-019-2041-8 |
Ejemplares similares
-
Axitinib Rechallenge Restores the Anticancer Effect after Nivolumab: A Case Report
por: Chang, Yueh-Shih, et al.
Publicado: (2023) -
Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012) -
Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019) -
Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021) -
Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)